BACKGROUND: Hypoxia, which is commonly observed in areas of primary tumours and of metastases, influences response to treatment. However, its characterisation has so far mainly been restricted to the ex vivo analysis of tumour sections using monoclonal antibodies specific to carbonic anhydrase IX (CA IX) or by pimonidazole staining, after the intravenous administration of this 2-nitroimidazole compound in experimental animal models. METHODS: In this study, we describe the generation of high-affinity human monoclonal antibodies (A3 and CC7) specific to human CA IX, using phage technology. RESULTS: These antibodies were able to stain CA IX ex vivo and to target the cognate antigen in vivo. In one of the two animal models of colorectal cancer studied (LS174T), CA IX imaging closely matched pimonidazole staining, with a preferential staining of tumour areas characterised by little vascularity and low perfusion. In contrast, in a second animal model (SW1222), distinct staining patterns were observed for pimonidazole and CA IX targeting. We observed a complementary pattern of tumour regions targeted in vivo by the clinical-stage vascular-targeting antibody L19 and the anti-CA IX antibody A3, indicating that a homogenous pattern of in vivo tumour targeting could be achieved by a combination of the two antibodies. CONCLUSION: The new human anti-CA IX antibodies are expected to be non-immunogenic in patients with cancer and may serve as broadly applicable reagents for the non-invasive imaging of hypoxia and for pharmacodelivery applications.
Monoclonal antibodies and their derivatives are increasingly being used in anticancer therapeutic strategies for the selective delivery of bioactive agents (e.g., full immunoglobulins for Fc-mediated cell killing, drugs with cleavable linkers, radionuclides, photosensitizers, pro-coagulant factors, cytokines) to the tumour environment, thus sparing normal tissues (Payne, 2003; Adams and Weiner, 2005; Neri and Bicknell, 2005; Carter, 2006; Schrama et al, 2006; Schliemann and Neri, 2007; Carter and Senter, 2008) . Although originally monoclonal antibodies specific to membrane antigens on cancer cells have been used for tumour targeting applications, alternative targets such as markers of angiogenesis (Schnitzer, 1998; Thorpe, 2004; Neri and Bicknell, 2005) , stromal antigens (Hofheinz et al, 2003; Rybak et al, 2007; Schliemann and Neri, 2007) and intracellular proteins released at sites of necrosis (Miller et al, 1993; Street et al, 2006) are increasingly being considered. In all these cases, antibody-mediated pharmacodelivery options are particularly attractive in consideration of the fact that most conventional cytotoxic agents and many therapeutic proteins exhibit a reduced uptake at the tumour site, compared to normal organs (Bosslet et al, 1998; Tarli et al, 1999) . Human or humanised monoclonal antibodies are preferred for targeting applications, as they are less immunogenic compared with rodent or chimeric antibodies (Hale et al, 1988; Winter et al, 1994) .
Solid tumours are heterogenous masses and the characterisation of the different microenvironments within a neoplastic lesion provides information about the tumour structures, which can be targeted in vivo with intravenously (i.v.) administered monoclonal antibodies to induce a therapeutic response. In this context, the characterisation of hypoxic regions within solid tumour masses assumes a particular relevance, because hypoxic cancer cells are less sensitive to certain killing agents (e.g., radiation and cytotoxic compounds; (Weinmann et al, 2004; Bertout et al, 2008) ). Hypoxic regions in tumours of experimental animal models can be assessed post-mortem by analysis of tissue sections, following i.v. administration of pimonidazole, a 2-nitroimidazole compound, which is selectively reduced and binds to intracellular macromolecules in hypoxic regions at pO 2 o 10 mm Hg (Dearling et al, 2004) . However, it would be desirable to complement this invasive procedure with a molecular imaging approach based on selective ligands to accessible proteins overexpressed at sites of hypoxia. Based on transcriptomic profiling of cells exposed to different oxygen concentrations, our group and others had recognised that carbonic anhydrase IX (CA IX) is one of the most overexpressed genes in hypoxic conditions (Staller et al, 2003; Scheurer et al, 2004) . In parallel, ex vivo staining of tumour sections with monoclonal antibodies specific to CA IX had revealed staining patterns overlapping (though somewhat broader) with the neoplastic regions stained with pimonidazole (Olive et al, 2001; Hoskin et al, 2003; Sobhanifar et al, 2005; Jankovic et al, 2006; Li et al, 2007) .
The functional contribution of CA IX to tumour growth and progression has long been debated (Pouyssegur et al, 2006; Brahimi-Horn et al, 2007) . Very recently, Pouyssegur and coworkers have reported that the simultaneous invalidation of CA IX and CA XII using short hairpin RNA technology led to a substantial growth retardation in transfected LS174T colorectal cancer xenograft models, whereas the individual knockouts yielded a substantially lower tumour growth retardation (Chiche et al, 2009) .
Monoclonal antibodies have also been used to achieve a selective in vivo localisation on cells, which display a high constitutive expression of CA IX (van Dijk et al, 1991; Chrastina et al, 2003a Chrastina et al, , 2003b Brouwers et al, 2004; van Schaijk et al, 2005) , especially kidney cancer cells, in which mutations in the gene encoding the von Hippel-Lindau tumour suppressor (pVHL) lead to a constitutive HIF-1a activation and, as a consequence, to a strong upregulation of CA IX on all tumour cells (Wykoff et al, 2000; Mazure et al, 2004) . This target was also detected as one of the most prominent accessible markers of renal cell carcinoma (RCC) in a chemical proteomic study, based on the ex vivo perfusion of surgically resected human kidneys with cancer using an active ester derivative of biotin, followed by capture of biotinylated proteins and mass spectrometric analysis (Castronovo et al, 2006) .
Although hypoxic areas can be efficiently stained with CA IX antibodies ex vivo, at the beginning of this study, it was not known whether the same structures could be targeted in vivo, considering that they are typically located at a 100 -200 mm distance from the nearest tumour blood vessel (Kerbel and Folkman, 2002) and thus may be more difficult to reach. Indeed, although the antibodybased targeting of markers of tumour neo-vasculature is a rapid and efficient process (e.g., L19 antibody specific to the alternatively spliced EDB domain of fibronectin; Viti et al, 1999; Borsi et al, 2002 Borsi et al, , 2003 Berndorff et al, 2005; Tijink et al, 2006) ), the tissue penetration of monoclonal antibodies to certain albuminal structures is often impaired by several factors, including molecular size (Yokota et al, 1992; Adams et al, 1998; Low et al, 2008) , antigen barrier (Dennis et al, 2007; El-Emir et al, 2007b) , and tumour interstitial pressure (Jain, 1987) . In this article, we describe the generation and characterisation of two high-affinity human monoclonal antibodies (A3 and CC7) specific to the extracellular carbonic anhydrase (CA) domain of human CA IX. Both antibodies were shown to selectively recognise CA IX on the surface of tumour cells in vitro, in tumour sections ex vivo and to preferentially localise at sites of hypoxia in vivo following i.v. administration.
MATERIALS AND METHODS

Cell lines
Cell culture media and supplements were purchased from Invitrogen (Basel, Switzerland).
The human colorectal adenocarcinoma cell lines LS174T (CL-188, ATCC) and HT-29 (HTB-38, ATCC) were maintained in DMEM and McCoy's 5A medium, respectively, supplemented with 10% fetal bovine serum (FBS) and antibiotic -antimycotic at 371C in an atmosphere of 5% CO 2 . The human glioblastoma cell line U87 (HTB-14, ATCC) was cultured in MEM medium, supplemented as described above. The human RCC cell line SK-RC-52 (Ebert et al, 1990) , a kind gift of Professor E Oosterwijk, was cultured in RPMI medium, supplemented as described above. The human colorectal adenocarcinoma cell line SW1222 was maintained in MEM medium supplemented with 10% FBS, 1% glutamine and 1% non-essential amino acids.
Cloning, expression, and purification of recombinant human CA IX The cDNA fragment encoding the carbonic anhydrase (CA) extracellular domain (aa 120-397) of CA IX was amplified from the full-length cDNA clone IRAUp969G1273D (imaGenes, Berlin, Germany) used as template with primers BW_CA9 (5 0 -GGAGATCC TCAAGAACCCCA-3 0 ) and FW_CA9_6xHis (5 0 -TTCCTCGAGTTA GTGATGGTGATGGTGATGACTGCTGTCCACTCCAGCAG-3 0 ) introducing a C-terminal 6xHis-tag. A secretion sequence, required for secretion into the extracellular medium, was amplified from the construct SIP(L19)-pcDNA3.1 (Borsi et al, 2002) using BW_SIP (5 0 -G ATAAGCTTGTCGACCATGGGCTGGAG-3 0 ) and FW_SIP (5 0 -TGG GGTTCTTGAGGATCTCCCGAGTGCACACCTGTGGAGA-3 0 ) primers. The resulting PCR fragments were gel-purified, assembled by PCR and cloned into vector pCEP4 (Invitrogen) by means of HindIII and XhoI digestion. The sequence-verified plasmid was used to transfect HEK 293 EBNA cell line using FuGENE 6 transfection reagent (Roche, Basel, Switzerland) . Transiently transfected cells were cultured in DMEM supplemented with 10% FBS and selected using 200 mg ml -1 of hygromycin (Invitrogen). The recombinant domain of CA IX was purified from supernatant by affinity chromatography on Ni-NTA agarose (Qiagen, Hombrechtikon, Switzerland) by means of the C-terminal 6xHis-tag. The purified protein was analysed by SDS -PAGE, size-exclusion chromatography using a Superdex 200 HR 10/30 column (GE Healthcare, Otelfingen, Switzerland). The specific activity of 1 mg recombinant protein was measured at 400 nm by its esterase activity as a surrogate of carbondioxide hydration activity (Pocker and Stone, 1967) , using 1 mM 4-nitrophenyl acetate as substrate in 100 ml 50 mM Tris/SO 4 2À pH 8.5. For biotinylation of recombinant CA IX EZ-Link Sulfo-NHS-LC-Biotin (Pierce, Rockford, IL, USA) was used according to the manufacturer's instructions.
Selections of antibodies from the ETH-2-Gold library
Selections of antibodies were carried out on Immunotubes (Nunc, Roskilde, Denmark) coated with recombinant CA IX at 50 mg ml -1 in PBS (20 mM NaH 2 PO 4 , 30 mM Na 2 HPO 4 , 100 mM NaCl, pH 7.4), as described previously by our group (Silacci et al, 2005) .
Recombinant antibody fragments, which were positive in ELISA, in the scFv format were expressed in E.coli TG-1 and purified from culture supernatant by affinity chromatography using Protein A Sepharose Fast Flow resin (GE Healthcare), as described previously (Silacci et al, 2005) .
Purified antibody fragments were analysed by SDS -PAGE and by size-exclusion chromatography on a Superdex 75 HR 10/30 column (GE Healthcare).
Construction of the affinity maturation libraries and selections of antibodies
The first affinity maturation library of scFv(A11) was cloned by introducing sequence variability in the CDR1 loops of both heavy and light chain. Antibody residues are numbered according to (Tomlinson et al, 1992) and (Williams et al, 1996) . Mutations at positions 31, 32, 33 of VH and 31, 31a, 32 of VL were introduced by PCR using the same partially degenerate primers (Eurofins MWG Operon, Ebersberg, Germany) as described previously (Villa et al, 2008) . A single round of selection on biotinylated antigen (final concentration 10 À7 M) was carried out eluting bound phage with 100 mM triethylamine, as described previously (Silacci et al, 2005) . ELISA and Biacore (Otelfingen, Switzerland) screening of dissociation profiles of selected clones on a high-density coated chip yielded the antibody A3.
In the construction of the second affinity maturation library, scFv(A3) was used as template. Sequence variability was introduced in the CDR2 loops of both heavy and light chain. Mutations at positions 52, 52a, 53, and 56 of VH and at positions 50. Positions 52 and 53 of VL were introduced using partially degenerate primers (Eurofins MWG Operon), as described by . A single round of selection on biotinylated antigen followed by a screening procedure, as described above, yielded the antibody CC7.
Biacore analysis
Affinity measurements were performed on a Biacore 3000 instrument (Biacore). 555 RU biotinylated recombinant CA IX were immobilised onto a streptavidin SA chip (Biacore). For the real-time interaction analysis peaks representing the monomeric fractions of scFv(A3) and scFv(CC7) were collected by sizeexclusion on a Superdex 75 HR 10/30 column (GE Healthcare) and injected at a flow of 20 ml min -1 on the low-density coated antigen chip. All kinetic data were evaluated using the BIAevaluation 4.1 software (Biacore).
Cloning, expression, and purification of antibodies in the SIP format ScFvs were converted into the SIP format by cloning VH and VL into pcDNA3.1 (Invitrogen) using the same primers and strategy as described by (Figure 1 ). The plasmids were transfected into CHO-S cells (Invitrogen) using Cell Line Nucleofector Kit V (Amaxa, Köln, Germany), following the manufacturer's protocol. Transfectomas were grown in RPMI supplemented with 10% FBS and selected by addition of 500 mg ml -1 Geneticin (G418) (Merck Chemicals Ltd, Nottingham, UK). Monoclonal cultures were obtained by fluorescent-activated cell sorting after staining for secreted antibody, as described (Zuberbühler et al, 2008) . After 14 days of selection, cells were brought into suspension, and cultured in Power CHO-CD 2 (Lonza, Basel, Switzerland). SIP antibodies were purified from culture medium by affinity chromatography using Protein A Sepharose Fast Flow resin (GE Healthcare), as described by (Zuberbühler et al, 2008) .
Fluorescence-activated cell sorting
Cells were harvested through incubation with 10 mM EDTA in PBS for 3 min at 371C. After counting and a centrifugation step of 5 min at 1100 r.p.m., cells were re-suspended in PBS supplemented with 2% FBS to a final concentration of 5 Â 10 6 cells per ml. Cells (1 Â 10 6 ) were then incubated for 30 min at room temperature with 1 mg ml -1 of SIP(A3) and SIP(CC7), respectively, in the presence of 2% FBS. For the detection, rabbit-anti-human IgE antibody (Dako, Glostrup, Denmark), followed by goat anti-rabbit IgG Alexa Fluor 488 antibody (Invitrogen) were used, diluted according to the manufacturer's recommendation. Rinsing with PBS was performed in between the incubation steps. Fluorescence-activated cell sorting (FACS) was performed on a FACSCanto equipped with FACSDiva software (BD Biosciences, Allschwil, Switzerland). A typical cell area was gated and a total of 10 000 events per sample were acquired. Omission of the primary antibody, as well as an isotype-matched control anti-lysozyme antibody, SIP(HyHEL-10) (Lavoie et al, 1992) , at 9 mg ml -1 were used to define background staining. Results were expressed in percentage of the maximal FACS signal. Data were analysed using FloJo software (Tree Star, Olten, Switzerland).
Immunofluorescence on frozen tissue sections
Healthy and tumour tissue was embedded in freezing medium (Microm, Volketswil, Switzerland), snap frozen in liquid nitrogen and stored at À801C until sectioned. Tissue sections (10 mm) were first fixed for 10 min in ice-cold acetone, rehydrated with PBS, blocked with FBS and then double-stained for CA IX and CD31. SIP(A3) and SIP(CC7), used as primary binding reagents at 1 mg ml (Silacci et al, 2005) was cloned into pHEN1 vector with VH and VL segments of scFvs flanked by the pelB secretion sequence, and an myc-tag followed by an amber codon and the geneencoding pIII. (B, E) Schematic representation of the different antibody formats used in this study. ScFv fragments consist of a variable heavy (VH) and a variable light (VL) chain connected by a peptide linker, whereas the small immunoprotein (SIP) (Borsi et al, 2002 ) is a disulfide-linked homodimer of two scFv -eCH4 fusions (C, F) SDS -PAGE analysis of the purified scFv(A3), scFv(CC7) and SIP(A3) and SIP(CC7), respectively, under reducing (R) and nonreducing (NR) conditions. (D) Cloning strategy for the SIP antibodies. Multi-fluorescence microscopy LS174T or SW1222 human colorectal adenocarcinoma cells (5 Â 10 6 ) were injected s.c. into the left flank of 6-to 8-week-old female MF1 nu/nu mice. Tumours were allowed to grow for 14 days to a size of typically 1 -1.5 cm 3 . All mice were injected i.v. into the tail vein with 100 mg of SIP(A3) (n ¼ 3) or SIP(CC7) (n ¼ 3) 6 h before killing. To relate anti-CAIX SIP antibody distribution to tumour morphology/ pathophysiology, the following parameters were studied by multi-fluorescence microscopy: (i) perfusion: the in vivo DNAbinding dye Hoechst 33342 (10 mg kg À1 ; Invitrogen) was injected i.v. 1 min before killing. (ii) Blood vessels: an anti-CD31 antibody was used to stain for blood vessel distribution. (iii) Hypoxia: the hypoxic cell marker pimonidazole hydrochloride (1-[(2-hydroxy-3-piperidinyl) propyl]-2-nitroimidazole hydrochloride; 60 mg kg À1 ; Natural Pharmacia International Inc., Burlington, MA, USA) was injected 30 min before killing.
Sections (12 mm) were first fixed in acetone for 10 min at room temperature and blocked for 20 mins with 3% normal goat serum (Dako). Three serial sections from the same tumour were incubated with a 1:2 dilution of rat anti-mouse CD31 simultaneously with one of the following antibodies: (1) 1 : 200 dilution of rabbit anti-pimonidazole (Natural Pharmacia International Inc.), (2) 1 : 1000 dilution of rabbit anti-human IgE (Dako; to detect the injected SIP(A3) and SIP(CC7)) or (3) 1 : 10 dilution of rabbit polyclonal anti-CAIX antiserum (sc-25599; Santa Cruz). After rinsing with PBS, sections were incubated with a 1 : 200 dilution of goat anti-rat Alexa Fluor 594 antibody and goat anti-rabbit IgG Alexa Fluor 488 (Invitrogen). Sections were mounted in PBS and viewed using an AxioImager.Z1 microscope (Carl Zeiss AG), fitted with a computer-controlled motorised stage. Images were captured by an AxioCam digital black and white camera using AxioVision 4.6 image analysis software (Carl Zeiss AG). Image processing was performed as described previously (El-Emir et al, 2007b) .
Biodistribution in LS174T human colorectal carcinoma model
LS174T human colorectal adenocarcinoma cells (1 Â 10 7 ) were injected s.c. into the left flank of 6-to 8-week-old female Balb/c nu/ nu mice (Charles River, Sulzfeld, Germany). Tumours were allowed to grow for 15 days to a weight of typically 200 mg. SIP(A3), SIP(CC7), SIP(HyHEL-10) and SIP(L19) were conjugated to p-isothiocyanatobenzyl-diethylene triamine pentaacetic acid (p-SCN-Bn-DTPA; Macrocyclics) in 0.1 M NaHCO 3 buffer at pH 8.2 by incubation with a 50-fold molar excess of p-SCN-Bn-DTPA for 1 h at room temperature. The p-SCN-Bn-DTPA-SIP conjugates were purified by size-exclusion on a PD-10 column (GE Healthcare). Mass spectrometric analysis revealed B1.8 modifications/antibody molecule.
The p-SCN-Bn-DTPA-SIP conjugates were labelled with 177 Lu (Perkin Elmer, Schwerzenbach, Switzerland) in a 125 mM ammonium acetate buffer pH 5.5 for 1 h at room temperature, as described by (Brouwers et al, 2004) . Subsequently, free 177 Lu was complexed by addition of 2.5 mM EDTA. The radiolabelled antibody preparation was purified by size-exclusion on a PD-10 column (GE Healthcare) and eluted with PBS. For all preparations, the rate of radiolabel incorporation and the immunoreactivity were determined, as described 
RESULTS
Isolation of A3 and CC7, two human monoclonal antibodies specific to CA IX The CA domain of CA IX (residues 120 -397) was cloned and expressed as soluble protein in HEK EBNA 293 cells (Figure 2A) and purified from the cell culture supernatant on Ni-NTA resin by means of a C-terminal 6xHis-tag. The native structure of CA IX on the cell membrane is reported to consist of cysteine-linked trimers (Pastorekova et al, 1992; Thiry et al, 2006) . We observed the formation of a covalent homodimer (B75%) and of a monomeric protein (B25%) both by SDS -PAGE analysis ( Figure 2B ) and by size-exclusion chromatography ( Figure 2C ). The specific esterase activity of the purified protein, as measured with 1 mM 4-nitrophenylacetate and 1.6 mg recombinant enzyme in 100 ml of 50 mM Tris-SO 4 , pH ¼ 8.5 containing 10 mM ZnSO 4 at 400 nm, was determined to be 1 nmol min À1 mg À1 ( Figure 2D ). This suggests that the enzyme is also catalytically active in terms of carbondioxide hydration. The recombinant catalytic domain of CA IX was used for the isolation of human monoclonal antibodies from the ETH-2-Gold phage antibody library (Silacci et al, 2005) . One of the clones isolated from the library ('A11') ( Table 1) , which was shown to be non-inhibitory in the enzymatic assay described above (data not shown), was affinity-matured by combinatorial mutagenesis of residues in the CDR1 loops of VH and VL domains according to a procedure recently developed by our group (Villa et al, 2008) , yielding clone A3. Additional mutagenesis of CDR2 loops led to the isolation of the daughter antibody clone CC7 (Table 1 ). The A3 and CC7 antibodies were expressed as scFv fragment in E.coli and in small immunoprotein (SIP) format in CHO-S cells using published procedures (Borsi et al, 2002 ) and purified to homogeneity by protein A affinity chromatography (Figure 1 ). The scFv format is particularly suitable for affinity determination using Biacore technology, whereas the homobivalent SIP format has been shown to offer distinctive advantages for in vivo molecular imaging applications (Borsi et 
In vitro characterisation of A3 and CC7 antibodies
The monomeric fractions of the A3 and CC7 antibodies in recombinant scFv format were isolated by size-exclusion chromatography and analysed by real-time interaction analysis on a Biacore instrument, using a microsensor chip coated with the recombinant CA domain of CA IX. Figure 3 illustrates sensograms for the two antibodies, revealing a
The ability of the two antibodies in SIP format to recognise the native CA IX on the surface of tumour cells was investigated by fluorescence-activated cell sorting (FACS), in comparison to a recombinant SIP antibody of irrelevant specificity (HyHEL-10; (Lavoie et al, 1992) . Figure 4 shows that a partial shift in the FACS profile was observed for the colorectal cancer cell line LS174T, whereas a very marked increase of cell fluorescence was detected for the pVHL-defective human RCC cell line SK-RC-52, similar to what previously reported for the clinical-stage cG250 monoclonal antibody (Grabmaier et al, 2000) .
A3 and CC7 were then tested by immunofluorescence for their ability to detect CA IX in a panel of xenografted human tumour tissue sections. Figure 5 shows the staining obtained with A3 only, because both antibodies performed equally well. As positive control, a commercial polyclonal anti-CA IX antiserum was used. A representative positive and negative control is shown for the LS174T tumour. A strong CA IX staining (green) was detectable in the colorectal cancer models LS174T and HT-29 at a distance of B100 mm from tumour blood vessels (red). In contrast, virtually all tumour cells in SW 1222 colorectal carcinoma, U87 glioma, and in SK-RC-52 renal cell carcinomas exhibited a strongly positive CA IX staining. However, although SW 1222 and U87 exhibited a defined vascular structure, CD31 staining in SK-RC-52 tumours yielded an irregular staining network. Other cancer types displayed a weaker level of CA IX staining (e.g., NCI-H460 human non-small cell lung carcinoma), whereas MCF-7 breast tumours and Ramos lymphomas were essentially negative (data not shown).
A3 and CC7 selectively target hypoxic tumour regions in vivo
To investigate whether the new human anti-CA IX antibodies were able to selectively localise to the antigen in tumours, following i.v. administration in the tail vein, we used both fluorescence microscopy and radioactivity-based detection methods. As mouse models of human cancer, we chose LS174T and SW1222 tumours: two colorectal cancer models, which have previously been extensively studied using monoclonal antibodies specific to the carcinoembryonic antigen (El Emir et al, 2007a; Fidarova et al, 2008) and with the vascular-targeting anti-EDB antibody L19 (El-Emir et al, 2007b) . Figure 6 shows representative results of a multi-colour fluorescence microscopy analysis of serial sections from LS174T tumours, following i.v. administration of SIP(A3) (6 h before killing of the mice), of pimonidazole (30 min before killing) and Hoechst 33342 (1 min before killing). The low magnification images (top panels) yield an informative impression of the heterogeneity of these tumours. One can recognise areas with dense vascular structures (red), some of which are well perfused 
Positions that are mutated in the primary antibody library (ETH-2-Gold) are underlined. Residues in A3 and CC7, mutated during the affinity maturation procedure, are in boldface. CC7 revealed an additional mutation (R instead of K) at position 39 in the VL chain sequence. Single amino acid codes are used according to standard IUPAC nomenclature.
a Numbering according to (Tomlinson et al, 1992 ) and (Williams et al, 1996) .
(blue). The structures targeted in vivo by SIP(A3) closely match those stained ex vivo for pimonidazole modification, confirming that these hypoxic areas could be reached by the i.v. administered antibody. Importantly, these areas are superimposable to the structures stained ex vivo with a polyclonal anti-CA IX antiserum, thus indicating that CA IX-positive areas of the tumour could be reached by our reagent. A higher magnification view (bottom panels) shows details of well perfused areas with no detectable CA IX expression, as well as tumour regions efficiently targeted by the A3 antibody. Similar results were obtained with SIP(CC7) (Supplementary Figure) .
The selective tumour targeting of the human anti-CA IX antibodies was also evaluated by immunofluoresence, comparing sections of tumours and of normal organs, 6 h after i.v. administration of SIP(A3). Figure 7 shows that a much brighter fluorescence signal was observed in tumour lesions, compared with normal organs (heart, intestine, kidney, liver, lung, and spleen). Figure 8 presents a similar analysis for the in vivo targeting of SW1222 tumours. In this model, one can observe a striking difference between external, well-perfused areas (blue) and complementary, poorly perfused hypoxic regions in the tumour core. Although an ex vivo analysis with the anti-CA IX antiserum yields a pattern with uniform staining intensity, the regions targeted in vivo by SIP(A3) mainly cluster around central vascular structures, with a gradient of staining intensity (green) which reflects a gradient in antibody diffusion. Interestingly, in this tumour model, pimonidazole staining and CA IX staining do not always overlap. Similar results were obtained with SIP(CC7) (Supplementary Figure) .
To assess the efficiency of in vivo targeting of CA IX, we performed a comparative biodistribution analysis with SIP(A3), SIP(HyHEL-10) used as negative control and SIP(L19), a clinicalstage antibody which recognises tumour neo-vascular structures (Borsi et al, 2002; Berndorff et al, 2005; Tijink et al, 2006; El-Emir et al, 2007b; Sauer et al, 2009 ). We used antibody preparations labelled with lutetium-177 rather than radioiodine, as previous studies had suggested that anti-CA IX antibodies are deiodinated upon internalisation (Brouwers et al, 2004) . Table 2 presents the biodistribution results for the three antibodies in LS174T tumour-bearing mice, 24 h after i.v. administration. Targeting data are expressed both as tumour/organ ratios and percent injected antibody dose per gram of tissue (% ID g À1 )±s.e.. At this time point, SIP(L19) displayed a tumour accumulation of 9.3 %ID g À1 , with a tumour/blood ratio of 5.8. SIP(A3) exhibited a lower tumour uptake (2.4 %ID g À1 ), but a better tumour/blood ratio (16.7). The negative control antibody displayed lower tumour uptake (1.1 %ID g À1 ), in line with previous studies .
DISCUSSION
In this study, we describe the isolation of the first fully human monoclonal antibodies (A3 and CC7) with high affinity to CA IX. Furthermore, the in vivo distribution and tumour-targeting properties of the two antibodies have been investigated using both fluorescence-based techniques and radiolabelled antibody preparations.
Monoclonal antibodies represent the most rapidly growing sector of Pharmaceutical Biotechnology (Walsh, 2006) , particularly for cancer therapy applications. As antibodies recognise their cognate antigens with exquisite selectivity, intense research efforts are devoted to the exploitation of these binding specificities for the development of superior therapeutic agents (Carter, 2006) . As rodent and chimeric antibodies are immunogenic in patients, there is an increased need for good quality human monoclonal antibodies, which can be used for imaging and therapeutic purposes (Winter and Harris, 1993; Pendley et al, 2003; Presta, 2006) . Both A3 and CC7 are fully human antibodies, which recognise human CAIX in its native conformation with affinities in the low nanomolar range. Interestingly, it was necessary to express the recombinant antigen in a mammalian system, as previous attempts to generate anti-CA IX antibodies from bacterially produced catalytic domain led to the isolation of antibody clones, which did not recognise the antigen in its native conformation (data not shown). With the newly reported A3 and CC7 antibodies CA IX was shown to be expressed heterogeneously throughout the majority of the studied tumours, with exception of renal cell carcinomas in which all cancer cells express the antigen as a consequence of a mutated VHL gene (Rathmell and Chen, 2008) (Figure 5 ). The hypoxia-related CA IX expression was usually detectable at a distance4100 mm from the nearest oxygen-supplying blood vessel. This finding is in agreement with previous reports (Hockel et al, 1996; Wykoff et al, 2000 Wykoff et al, , 2001 Beasley et al, 2001; Koukourakis et al, 2001; Loncaster et al, 2001) and in accordance with the diffusion limit of oxygen within tissues, which has been measured to be around 150 mm (Folkman et al, 2000; Vaupel, 2004) . The A3 and CC7 antibodies do not inhibit CA IX activity and do not bind to CA XII, which is upregulated along with CA IX under hypoxic conditions and which shares only 39% sequence identity with CA IX. In general, the choice of non-inhibitory antibodies represents a useful general precaution for antibodies specific to targets (e.g., matrix metalloproteinases), where endogenous inhibitors may compromise in vivo localisation performance of the antibody. To implement biomedical strategies aimed at the simultaneous inhibition of CA IX and CA XII activities Chiche et al, 2009 (Cancer Res., 69, 358 -368) , the use membraneimpermeable sulfonamides, which display inhibitory constants in the low nanomolar range both towards CA IX and CA XII may be preferable (Svastová et al, 2004; Cecchi et al., 2005; Dubois et al, 2007; Supuran, 2008; Ahlskog et al, 2009) .
By multi-fluorescence microscopy we subsequently demonstrated that the A3 and CC7 antibodies, in recombinant SIP format, preferentially localised to hypoxic areas of LS174T and SW1222 colorectal tumour xenografts 6 h after i.v. administration. The tumour uptake was dramatically more efficient compared with normal organs, which displayed minimal staining at the same time point, using an immunofluorescence detection method (Figure 7 ). In the LS174T model an excellent overlap was observed between pimonidazole staining and structures targeted in vivo by the anti-CA IX antibodies in all studied animals, although A3 and CC7 appeared to stain slightly closer to the vasculature than did the pimonidazole. The targeted structures were furthermore superimposable to the staining pattern of an ex vivo applied commercially available polyclonal anti-CA IX antiserum. In the SW1222 model CA IX expression was consistently detected in a much broader area with the A3 and CC7 antibodies compared with the one covalently modified by pimonidazole (Figure 8 and Supplementary Figure) . In these tumours, both A3 and CC7 showed reduced accumulation compared with the ex vivo applied commercial anti-CA IX antiserum, and were in close proximity to both large and small vascular structures. This may indicate a barrier preventing a homogenous targeting of antigen within the tumour mass, although other tumour factors may also be involved. Interestingly, these large vascular structures were only poorly perfused with the Hoechst dye.
To our knowledge, this is the first study in which pimonidazole staining, CA IX targeting (both in vivo and ex vivo) and perfusion are simultaneously analysed. As the time points for the injection of antibody, pimonidazole and Hoechst 33342 were different (6 h, 30 min and 1 min before killing, respectively), we cannot exclude that a transient occlusion of certain vascular structures took place (Chaplin et al, 2006) .
Limitations in antibody diffusion within solid tumour masses have previously been reported for reagents used in the IgG format (Adams and Weiner, 2005; Dennis et al, 2007; El Emir et al, 2007a) , mainly in relation to the so-called 'antigen barrier'. In this study, we have used antibodies in SIP format (Borsi et al, 2002; Villa et al, 2008) , as this format and similar mini-antibody formats have extensively been shown to offer distinctive advantages both for imaging applications (Leyton et al, 2009); von Lukowicz et al, 2007; Wei et al, 2008) and for radioimmunotherapy of cancer (Berndorff et al, 2005; Tijink et al, 2006; Kenanova et al, 2007; Sauer et al, 2009) . Recent publications suggest that smaller high-affinity ligands (MW o 2000 Da) may enjoy a much more rapid tissue distribution compared with antibodies and antibody fragments (Low et al, 2008) . High-affinity low-molecular weight ligands to CA IX have been reported (Supuran, 2008) and it will be interesting to compare their in vivo tumour targeting properties with those of the human antibodies A3 and CC7 with a molecular weight of 76 kDa.
In our biodistribution studies we have used lutetium-177 as radionuclide, in light of previous reports indicating that dehalogenation takes place with internalising anti-CA IX antibodies (Brouwers et al, 2004) . With this radiometal, we observed high kidney and liver values (Table 2) , similar to what we had previously reported for the 177 Lu-labelled L19 antibody in SIP format (Tijink et al, 2006) . In the pairwise comparison presented in this article, L19 appeared to yield higher tumour uptake values, yet at the expense of a slower blood clearance. Tumour pre-targeting strategies could also be considered, as they have yielded excellent tumour/organ ratios over a range of time points after injection (van Schaijk et al, 2005) . By contrast, Fab and F(ab') 2 preparations of the same antibody did not exhibit improved selectivity compared with the IgG format (van Dijk et al, 1991) .
Our group has developed and brought to clinical trials human monoclonal antibody derivatives based on the L19 (Pini et al, 1998) , F8 (Villa et al, 2008) and F16 antibodies, specific to splice isoforms of fibronectin and of tenascin-C, respectively. These antibodies display comparable in vivo biodistribution results and can target a broad variety of tumours. However, their uptake within the solid tumour mass is confined to the subendothelial extracellular matrix (Demartis et al, 2001; Borsi et al, 2002; El-Emir et al, 2007b; Villa et al, 2008) . The human anti-CA IX antibodies appear to target a similarly broad spectrum of cancers, yet with a four-times lower tumour uptake and a broader tissue distribution within the lesion. For this reason, one could envisage the simultaneous use of vascular-targeting and hypoxia-targeting antibodies for pharmacodelivery applications, to achieve a more homogenous distribution to a therapeutic agent (e.g., cytotoxic drug; (Wu and Senter, 2005; Carter and Senter, 2008) ) within the tumour mass. Health Research/Cancer Research UK (Grant no. C34/A7279), is gratefully acknowledged.
The human RCC cell line SK-RC-52 was a kind gift from Professor E Oosterwijk (Radbound University Nijmegen Medical Centre, Nijmegen, The Netherlands). The anti-CD31 antibody, used for the multi-fluorescence microscopy studies, was a kind gift Tumour/organ ratios, at 24 h after i.v. injection, are indicated in boldface. The numbers in brackets correspond to the percent injected antibody dose per gram of tissue (% ID/g) ± s.e. Student's t-test was applied to calculate significant differences. The tumour uptake of SIP(A3) is significantly higher than the one of the anti-lysozyme antibody SIP(HyHEL-10) (Po0.001).
Pimonidazole SIP(A3) (in vivo)
Anti-CA IX (ex vivo) 
